Versarian plc could be a millionaire-maker in 2018

Harvey Jones understands the current excitement about surrounding Versarian plc (LON: VRS) but he also recognises the risks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Advanced materials group Versarien (LSE: VRS) has excited the attentions of investors in recent months after its share price quadrupled from 21p to 80p in just a fortnight. Everybody loves a three-bagger, but the problem is most people love them too late. Does it still have millionaire-maker potential?

The right stuff

My colleague GA Chester made a good job of explaining why Versarien flew to the skies in his recent article. Briefly, in November and early December it announced new partnerships with an unnamed global consumer goods company and US-headquartered global chemicals supplier, plus ongoing advanced negotiations with several multinational companies across various sectors. It is all down to the magic word graphene. 

Versarien uses proprietary materials technology to create game-changing engineering solutions for blue-chip companies, for use across a broad variety of industry sectors. The quality of its graphene, coupled with its research capabilities in the universities of Manchester and Cambridge, is attracting interest from multinational blue-chips, who are keen to commercialise its developments.

Funds, funds, funds

Versarien also successfully raised £2.9m in November to fund its expansion. The fundraising, which was oversubscribed, was a welcome boost given its dwindling cash balance. This fell from £1.51m on 30 September 2016 to just £350,000 last September.

Versarien recently published a buoyant set of interims, showing group revenues rising 167% to £4.38m, up from £1.64m in the first half of 2016. Its loss before tax almost halved from £1.47m to £770,000. Net assets totalled £5.72m, up slightly from £5.14m in 2016. My worry is that investors are putting a high price on future success with the AIM-listed company’s market cap a pretty meaty £92m. Given that it has been recently making a loss, and was down to its last £350,000, there is a lot of hope built into that valuation. 

Nano technology

The group’s fortunes are also dependent on the success of its own clients. For example, it has a collaboration with CT Engineering in the aerospace industry, which was exposed to the recent decline in the oil and gas sector. This had a knock-on impact on Versarian’s revenues in 2016, which fell from £2.36m to £1.66m as a result. However, with the oil price climbing, its prospects now look brighter.

Versarian recently launched a promising collaboration with Israel Aerospace Industries to supply and test its proprietary Nanene few-layer graphene nano-platelets in aerospace composite structures, and it opened a US sales office in Palo Alto to exploit significant opportunities in the region. 

Spikey

Versarien is progressing on a number of fronts, and the future looks promising. The share price has dipped slightly following recent excitement as investors take profits and await the next announcement. Currently, it trades at 63p. You could wait for further news before committing funds, but the problem is that if the news is good the share price may spike before you have time to click ‘buy’. It will be riskier buying today, but potentially more rewarding if your nerves can take it.

What really counts right now is commercial opportunities offered by graphene. That is hard for outsiders to judge. Probably one for your watchlist, rather than to dive into today.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »